RIGL - Rigel Pharmaceuticals, Inc.
| Previous Close | 2.0200 |
| Open | 2.1700 |
| Bid | 2.10 x 3200 |
| Ask | 2.11 x 1300 |
| Day's Range | 2.0799 - 2.2000 |
| 52 Week Range | 1.9600 - 4.6800 |
| Volume | 1,460,074 |
| Avg. Volume | 2,296,285 |
| Market Cap | 346.611M |
| Beta (3Y Monthly) | 1.36 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.64 |
| Earnings Date | Jul 30, 2018 - Aug 3, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.07 |
- ACCESSWIRE•51 minutes ago
4 Healthcare Stocks Making Moves On Wednesday (1/23/19)
CORAL GABLES, FL / ACCESSWIRE / January 23, 2019 / The future of healthcare stocks, and the medical sector industry as a whole, is solely dependent on the ability of medical experts and healthcare professionals to work to provide the best quality of care for patients in the space. With the rise of global population, coupled with depletion of most common resources, consumer access to healthcare is crucial to securing the health and wellness of all living people, resulting in a need for companies in the space to meet these demands. As companies in the healthcare industry work to better understand the needs of their patients, the sector, in its entirety, may boast impressive opportunities for investors looking to the space.
- MarketWatch•3 hours ago
Rigel Pharmaceuticals stock up 9% after announcing licensing agreement with Grifols
Shares of Rigel Pharmaceuticals Inc. shot up 9% in premarket trade Wednesday after the company announced it had entered a license and supply agreement with Spain-based Grifols, S.A. to commercialize fostamatinib disodium hexahydrate, its treatment for thrombocytopenia in adult patients. It is commercially available in the U.S. under the brand name Tavalisse. Under the terms of the agreement, Rigel will receive a $30 million upfront cash payment, with a potential $297.5 million in payments upon reaching certain regulatory and commercial milestones. That figure includes a potential $20 million payment upon the European Medicines Agency approving fostamatinib for the treatment of chronic idiopathic thrombocytopenic purpura (ITP). Rigel will also receive royalty payments based on tiered net sales, which the company said could reach 30% of net sales. In return, Grifols will receive exclusive rights to fostamatinib in Europe and Turkey. However, if fostamatinib has not been approved by the EMA for the treatment of ITP by 2021, Grifols will have the option to terminate the entire agreement, the companies said, and Rigel will have to pay Grifols $25 million to regain all rights to fostamatinib in Europe and Turkey. Rigel shares have fallen 12% in the year to date through Tuesday, while the iShares Nasdaq Biotechnology ETF has gained 12.7%. The S&P 500 has gained 5%.
- PR Newswire•3 hours ago
Rigel Pharmaceuticals Enters Collaboration and License Agreement with Grifols, S.A. to Commercialize Fostamatinib in Europe
- Grifols gains exclusive rights to fostamatinib in all potential indications in Europe and Turkey - Rigel to receive an upfront payment of $30 million , with the potential for $297.5 million in total ...
- Simply Wall St.•8 days ago
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL): When Will It Breakeven?
Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL): Rigel Pharmaceuticals, Inc., a biotechnology company, engages in the discovery and development of small molecule drugs for the treatment of immune and hematologic disorders, cancer, and Read More...
- PR Newswire•16 days ago
Rigel Pharmaceuticals Provides Business Update
SOUTH SAN FRANCISCO, Calif., Jan. 7, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (RIGL) today provided a business update, including the quantity of TAVALISSE™ bottles sold in 2018 and its cash position as of December 31, 2018, as well as an overview of its strategy for 2019. The company's president and CEO, Raul Rodriguez, will provide a more detailed company overview during his presentation at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9 at 11:00am PT. The ongoing execution of our TAVALISSE commercial strategy will be a key focus in 2019," said Mr. Rodriguez.
- PR Newswire•20 days ago
Rigel to Present at the 37th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO , Jan. 3, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez , the company's president and CEO, is scheduled to present a company overview ...
- Insider Monkey•last month
Rigel Pharmaceuticals, Inc. (RIGL): Hedge Fund Sentiment Unchanged
Hedge funds and other investment firms run by legendary investors like Israel Englander and Ray Dalio are entrusted to manage billions of dollars of accredited investors’ money because they are without peer in the resources they use to identify the best investments for their chosen investment horizon. Moreover, they are more willing to invest a […]
- Benzinga•last month
Biotechs Were Innovators In 2018: Here Are The Top New Molecules That Were Approved
Health care stocks are among a handful of sectors bucking the broader market downturn in 2018. Biotechs, though down for the year, have suffered less damage than other stocks. One factor that worked in ...
- PR Newswire•2 months ago
Rigel to Present at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference in New York City
SOUTH SAN FRANCISCO, Calif. , Dec. 5, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Dean Schorno , the company's executive vice president and chief financial officer, ...
- GlobeNewswire•2 months ago
New Research Coverage Highlights Weight Watchers International, Rudolph Technologies, Lowe's Companies, Net 1 UEPS Technologies, Viasat, and Rigel Pharmaceuticals — Consolidated Revenues, Company Growth, and Expectations for 2018
NEW YORK, Dec. 03, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Simply Wall St.•2 months ago
What does Rigel Pharmaceuticals Inc’s (NASDAQ:RIGL) Balance Sheet Tell Us About Its Future?
Rigel Pharmaceuticals Inc (NASDAQ:RIGL), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is RIGL Read More...
- Zacks•2 months ago
Implied Volatility Surging for Rigel Pharmaceuticals (RIGL) Stock Options
Investors need to pay close attention to Rigel Pharmaceuticals (RIGL) stock based on the movements in the options market lately.
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of RIGL earnings conference call or presentation 6-Nov-18 10:00pm GMT
Q3 2018 Rigel Pharmaceuticals Inc Earnings Call
- Zacks•3 months ago
Rigel Pharmaceuticals (RIGL) Reports Q3 Loss, Tops Revenue Estimates
Rigel (RIGL) delivered earnings and revenue surprises of 12.50% and 38.41%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•3 months ago
Rigel: 3Q Earnings Snapshot
On a per-share basis, the South San Francisco, California-based company said it had a loss of 14 cents. The results exceeded Wall Street expectations. The average estimate of four analysts surveyed by ...
- PR Newswire•3 months ago
Rigel Announces Third Quarter 2018 Financial Results and Provides Company Update
Reports TAVALISSE™ (fostamatinib disodium hexahydrate) net product sales of $4.9 million Conference call and webcast today at 5:00PM Eastern Time SOUTH SAN FRANCISCO, Calif. , Nov. 6, 2018 /PRNewswire/ ...
- PR Newswire•3 months ago
Rigel to Present Data on Fostamatinib in Three Presentations at the 60th American Society of Hematology Annual Meeting & Exposition
Data related to fostamatinib accepted for oral presentation and two poster presentations SOUTH SAN FRANCISCO, Calif. , Nov. 1, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced ...
- PR Newswire•3 months ago
Rigel Announces Conference Call and Webcast to Report Third Quarter 2018 Financial Results
SOUTH SAN FRANCISCO, Calif. , Oct. 30, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its third quarter 2018 financial results after market close on ...
- PR Newswire•3 months ago
Rigel Pharmaceuticals Enters Collaboration and License Agreement with Kissei Pharmaceutical Co., Ltd. to Develop and Commercialize TAVALISSE™ (fostamatinib disodium hexahydrate) in Japan and other Asian Countries
SOUTH SAN FRANCISCO, Calif., Oct. 29, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (RIGL) today announced that it had entered into an exclusive license and supply agreement with Kissei Pharmaceutical Co., Ltd. ("Kissei") to develop and commercialize TAVALISSE™ in all current and potential indications in Japan, China, Taiwan and the Republic of Korea. Kissei is a Japan-based pharmaceutical company addressing patients' unmet medical needs through its research, development and commercialization efforts, as well as through collaborations with partners.
- Simply Wall St.•3 months ago
How Rigel Pharmaceuticals Inc (NASDAQ:RIGL) Can Impact Your Portfolio Volatility
If you’re interested in Rigel Pharmaceuticals Inc (NASDAQ:RIGL), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could Read More...
- Zacks•3 months ago
Rigel (RIGL) Gets EMA Acceptance for Thrombocytopenia Drug
The EMA validates Rigel Pharmaceuticals' (RIGL) marketing application for thrombocytopenia drug, Tavalisse.
- PR Newswire•3 months ago
Rigel Receives EMA Validation of the Marketing Authorization Application for Fostamatinib Disodium Hexahydrate in Chronic Immune Thrombocytopenia (ITP) in Adult Patients
First SYK inhibitor for the treatment of adult chronic ITP SOUTH SAN FRANCISCO, Calif. , Oct. 11, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that the European Medicines ...
- PR Newswire•4 months ago
Rigel to Host Investor & Analyst Day in New York City on October 4, 2018
SOUTH SAN FRANCISCO, Calif. , Sept. 27, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) today announced that it will host an investor and analyst day event on Thursday, October 4, 2018 ...
- PR Newswire•4 months ago
Rigel to Present at the Cantor Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif. , Sept. 24, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez , the company's president and chief executive officer, is scheduled ...
